Efficacy of everolimus, a novel mTOR inhibitor, against basal-like triple-negative breast cancer cells.

@article{Yunokawa2012EfficacyOE,
  title={Efficacy of everolimus, a novel mTOR inhibitor, against basal-like triple-negative breast cancer cells.},
  author={Mayu Yunokawa and Fumiaki Koizumi and Yuka Kitamura and Yasufumi Katanasaka and Naoko Okamoto and Makoto Kodaira and Kan Yonemori and Chikako Shimizu and Masashi Ando and Kenkichi Masutomi and Teruhiko Yoshida and Yasuhiro Fujiwara and Kenji Tamura},
  journal={Cancer science},
  year={2012},
  volume={103 9},
  pages={
          1665-71
        }
}
Patients with triple-negative breast cancers (TNBCs) typically have a poor prognosis because such cancers have no effective therapeutic targets, such as estrogen receptors for endocrine therapy or human epidermal growth factor receptor 2 (HER2) receptors for anti-HER2 therapy. As the phosphatidylinositol 3' kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) cascade is activated in TNBCs, mTOR is a potential molecular target for anticancer therapy. In this study, we investigated the… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 44 CITATIONS